The Coronavirus is continuously changing its form. Due to this continuous change in the virus, doctors and scientists are advising rapid vaccination to avoid vaccine inefficiency. After the deadly second wave, another worrying news awaits the nation. According to a report, scientists have warned that the delta variant, also known as B.1.617.2, which caused havoc in the country in the second wave, has turned into a more dangerous variant than before. This changed variant is being called Delta Plus or AY.1. Scientists fear that even the monoclonal antibodies cocktail will not have an effect on this variant.
What is Monoclonal Antibodies Cocktail?
Monoclonal Antibodies Cocktail is a drug used in the treatment of COVID-19. However, it is treated only when the patient’s condition is at a very critical stage. This drug is manufactured jointly by the pharma company Cipla and Roche India. In India, it was approved in May for emergency use. The drug has previously received approval from the Central Drugs Standards Control Organization (CDSCO) for emergency use in the US and European Union countries.
What is the Delta Plus variant of Coronavirus?
The ‘delta plus’ variant of the coronavirus, caused by a mutation in the delta or ‘B.1.617.2’ variant, was first identified in India. It was responsible for the deadly second wave of the pandemic. However, there is no indication yet of how deadly the disease can be due to the new type of virus. Reportedly, this Delta Plus variant can resist the ‘Monoclonal Antibody Cocktail’ treatment that has recently been approved in India.
Till 7th June, 6 infection cases have come to the fore
According to a report by the UK health organization Public Health England (PHE), 63 genomes of the delta variant have been uncovered with the new K417N mutation. PHE came to know of Delta Plus during a routine check of changes in the Delta variant. According to this recent report on the virus’ variants, 6 cases of delta plus variant were reported in India till June 7.
The frequency of this variant is low in India
Dr Vinod Scaria of Delhi’s Institute of Genomics and Integrative Biology has said that the key concern about the K417N mutation is the evidence that it is resistant to Roche’s antibody cocktail. However, he also says that the frequency of K417N mutation is not very high in India.